Drugs / ARO-AAT
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03362242 Comparator | Mar → Oct 2018 | alpha 1-antitrypsin deficiency | Arrowhead Pharmaceuticals | Completed | No outcome recorded |
Press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-11-09 | Arrowhead Pharmaceuticals | Arrowhead Pharmaceuticals Presents Late-Breaking Clinical Data on ARO-AAT at Liver Meeting® 2018 arrowheadpharma.com ↗ |
| 2018-08-31 | Arrowhead Pharmaceuticals | Arrowhead Completes Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease arrowheadpharma.com ↗ |
| 2018-06-29 | Arrowhead Pharmaceuticals | Arrowhead Presents New Clinical Data on ARO-AAT at Alpha-1 National Education Conference arrowheadpharma.com ↗ |
| 2018-06-18 | Arrowhead Pharmaceuticals | Arrowhead Completes Enrollment in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease arrowheadpharma.com ↗ |
| 2018-03-12 | Arrowhead Pharmaceuticals | Arrowhead Begins Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease arrowheadpharma.com ↗ |
| 2018-02-22 | Arrowhead Pharmaceuticals | Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease arrowheadpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARO-AAT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03362242 ↗ |
| Route | Subcutaneous | “by subcutaneous (sc) injections” NCT03362242 ↗ |